S1726

1) The ASSIST Act of 2025 (S.1726) was introduced May 13, 2025 by Sen. Tuberville (R-AL) and reported favorably out of the Senate Veterans' Affairs Committee on March 18, 2026. It awaits floor action. A companion bill (HR1364) is identical and has been received in the Senate, increasing the probability of eventual enactment. The bill amends 38 U.S.C. §1701(6)(I) to explicitly include ramp/kneeling systems, raised roofs/doors/lowered floors, mobility lifts, wheelchair tiedowns, and adapted seating as 'medical services' for veterans. 2) The bill authorizes VA to provide these adaptations but does NOT appropriate a specific dollar amount — actual funding will flow through the VA Medical Services appropriations line in subsequent spending bills. This is an authorization bill creating statutory eligibility for a defined set of equipment. The mechanism is mandatory procurement: once a veteran's physician certifies medical necessity, VA must fund the adaptation rather than relying on discretionary grant programs like VA's existing automobile adaptive equipment program. This shifts the purchase from grant-based (uncertain) to entitlement-based (predictable) for eligible veterans. 3) Structural winners are $VMI (Valmont Industries) and $LCII (LCI Industries). $VMI manufactures ramp and kneeling systems directly listed in the bill — VA procurement would buy these products in volume. $LCII, through its Lippert Components mobility division, produces wheelchair tiedowns and adapted seating, also explicitly named. Both companies have existing products that now gain access to a guaranteed government buyer. No publicly traded company is structurally disadvantaged by this bill; it expands a spending program without offset or restriction. 4) Market data shows $VMI has surged +27.44% over the past 30 days, closing at $509.20 on April 30, 2026, within 0.04% of its 52-week high of $509.40. The rally began April 21, consistent with increasing attention to the ASSIST Act's committee markup and favorable report. $LCII has declined -3.29% over the same period to $118.93, despite the same legislative catalyst, suggesting the market has not fully priced in LCII's exposure. This divergence may represent an opportunity if the bill proceeds to passage. 5) Next steps: floor vote in the Senate, then conference with the House companion bill HR1364 (already passed House and received in Senate). Given committee approval, cosponsor count of 8, and bipartisan nature (veterans' healthcare expansion), passage probability in the 119th Congress is above 50%. Enactment would likely occur before the August 2026 recess.